SEC Form 10-K filed by LivaNova PLC
$LIVN
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2025 | $81.00 | Overweight | KeyBanc Capital Markets |
| 10/1/2025 | $55.00 | Buy → Neutral | Goldman |
| 5/20/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 2/26/2025 | Outperform → Peer Perform | Wolfe Research | |
| 10/4/2024 | $65.00 | Buy | Goldman |
| 9/17/2024 | $55.00 → $66.00 | Neutral → Outperform | Robert W. Baird |
| 3/20/2024 | Buy | Needham | |
| 2/20/2024 | $60.00 → $70.00 | Neutral → Buy | Mizuho |
KeyBanc Capital Markets initiated coverage of LivaNova with a rating of Overweight and set a new price target of $81.00
Goldman downgraded LivaNova from Buy to Neutral and set a new price target of $55.00
Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 – Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration – Received U.S. Food and Drug Administration approval for cloud-based digital health platform LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology com
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 901145. A
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup of the webcast. A replay will be available on the LivaNova website within 24 hours after the
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
10-K - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. "Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector," Makatsaria said. "With her extensive OSA market expertise, she has a strong track record in creating new sleep therapy pathways, improving patient access to care, and building strong commercial teams. Her leadership will help us unlock transformational growth by co
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board. "LivaNova is pleased to welcome Don to our Board of Directors," said William Kozy, Chair of the Board. "Over the course of 30 years, he has amassed expertise in finance, accounting, and strategy, much of which he honed while serving in leadership positions with global healthcare companies. His deep experience and knowledge will be welcome assets to the Board." Zurbay joins the LivaNova Board of Directors after a seven-year tenure at Patterson C
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
SC 13G - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 – Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration – Received U.S. Food and Drug Administration approval for cloud-based digital health platform LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology com
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 901145. A
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion – Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1) – Launched Essenz Perfusion System in China LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an organic basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per sh